Stock Research: Metropolis Healthcare

Peer-based, data-driven stock research by Obermatt enables quick and easy due diligence for your stock investing.

Metropolis Healthcare

NSEI:METROPOLIS INE112L01020
14
  • Value
    49
  • Growth
    64
  • Safety
    Safety
    27
  • Combined
    42
  • Sentiment
    13
  • 360° View
    360° View
    14
Unlock
Which ranks are driving this 360° View?
Subscribe to View
Company Description

Metropolis Healthcare Limited is an India-based company providing diagnostic services to patients, healthcare providers, and corporates. It operates in the pathology service industry, specializing in various pathological investigations including biochemistry, hematology, and microbiology, serving both B2B and B2C markets with over 4,000 tests. The company operates across India and Africa, with approximately 200 clinical laboratories and 4,300 service centers in 22 Indian states. In the last fiscal year, the company had a market cap of $1193 million, profits of $123 million, and revenue of $156 million.

more
Analysis

ANALYSIS: With an Obermatt 360° View of 14 (better than 14% compared with alternatives), overall professional sentiment and financial characteristics for the stock Metropolis Healthcare are critical, mostly below average. The 360° View is based on consolidating four consolidated indicators, with three out of four indicators below average for Metropolis Healthcare. The consolidated Growth Rank has a good rank of 64, which means that the company experiences above-average growth momentum when looking at financial metrics such as revenue, profit, and invested capital growth, as well as stock returns. It ranks higher than 64% of competitors in the same industry. The other indicators are below average, namely the Value, Safety, and Sentiment Ranks.The Value Rank at 27 means that the share price of Metropolis Healthcare is on the high side compared with its peers regarding revenues, profits, and invested capital. The stock price is higher than for 73% of alternative stocks in the same industry. The consolidated Safety Rank has a riskier rank of 49, which means that the company has a riskier financing structure than 51% comparable companies when looking at the amount of its debt, its refinancing requirements, and its ability to service debt. The consolidated Sentiment Rank also has a low rank of 13, indicating professional investors are more pessimistic about the stock than for 87% of alternative investment opportunities. ...read more

more
Index
The higher the 360° View, the better the stock performed against its peers, considering all metrics. The 360° View represents an average of the other 5 ranks and is then scaled to a rank from 1 to 100. The shaded values are illustrative only.
Last update: 13-Nov-2025.

Make Sense of the Ranks

The higher, the better. For every stock, we judge its performance against its peers and rank it on a scale of 1 to 100. These ranks are percentiles: a rank of 75 means the company outperforms 75% of its peers in that specific area. The higher the rank, the better the stock stacks up against its peers.

Detailed and Historical Ranks

Deep dive into 15 detailed ranks and 3 years of history. Unlock the analysis.

Unlock Ranks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2024 2023 2022
Value
27 23 12 5
Growth
64 59 55 97
Safety
Safety
49 46 41 73
Sentiment
13 25 27 18
360° View
360° View
14 20 12 51
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2024 2023 2022
Analyst Opinions
56 46 13 33
Opinions Change
22 8 50 37
Pro Holdings
n/a 12 56 47
Market Pulse
38 82 54 41
Sentiment
13 25 27 18
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2024 2023 2022
Value
27 23 12 5
Growth
64 59 55 97
Safety Safety
49 46 41 73
Combined
42 25 19 84
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2024 2023 2022
Price vs. Sales (P/S)
20 26 10 3
Price vs. Earnings (P/E)
37 28 19 5
Price vs. Book (P/B)
27 16 19 5
Dividend Yield
36 28 39 46
Value
27 23 12 5
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2024 2023 2022
Revenue Growth
76 88 74 74
Profit Growth
87 55 24 60
Capital Growth
19 50 59 100
Stock Returns
39 43 55 85
Growth
64 59 55 97
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2024 2023 2022
Leverage
56 54 52 70
Refinancing
19 19 17 33
Liquidity
54 60 56 75
Safety Safety
49 46 41 73

Similar Stocks

Discover high‑ranked alternatives to Metropolis Healthcare and broaden your portfolio horizons.

Maruti Suzuki

NSEI:MARUTI
Country: India
Industry: Automobile Manufacturers
Size: Large
Full Stock Analysis

UPL

BSE:512070
Country: India
Industry: Fertilizers & Agricultural Chemicals
Size: Large
Full Stock Analysis

Cipla

NSEI:CIPLA
Country: India
Industry: Pharmaceuticals
Size: Large
Full Stock Analysis

Kalbe Farma

IDX:KLBF
Country: Indonesia
Industry: Pharmaceuticals
Size: Medium
Full Stock Analysis

The Obermatt Advantage

Ready to Elevate Your Investing?
Get Started Today

Choose the Obermatt subscription that best fits your needs.


30-day money back guarantee. Your subscription will renew until you cancel it, which you can do at any time.